
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IST:SELEC.E

Operating Margin
Selcuk Ecza Deposu Ticaret ve Sanayi AS
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
TR |
![]() |
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IST:SELEC.E
|
60.8B TRY |
3%
|
|
US |
![]() |
Mckesson Corp
NYSE:MCK
|
88.7B USD |
1%
|
|
US |
![]() |
Cencora Inc
NYSE:COR
|
56.8B USD |
1%
|
|
US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
56.9B USD |
1%
|
|
US |
![]() |
Cardinal Health Inc
NYSE:CAH
|
38.1B USD |
1%
|
|
AU |
![]() |
Sigma Healthcare Ltd
ASX:SIG
|
32.4B AUD |
0%
|
|
CN |
![]() |
Huadong Medicine Co Ltd
SZSE:000963
|
78.6B CNY |
11%
|
|
CN |
![]() |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
70.4B CNY |
3%
|
|
KR |
![]() |
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
9%
|
|
US |
![]() |
Henry Schein Inc
NASDAQ:HSIC
|
8.4B USD |
6%
|
|
AU |
E
|
EBOS Group Ltd
OTC:EBOSY
|
8.2B USD |
4%
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
Glance View
In the dynamic landscape of Turkey's pharmaceutical industry, Selçuk Ecza Deposu Ticaret ve Sanayi A.Ş. stands as a formidable force, deftly operating as a bridge between pharmaceutical manufacturers and healthcare providers. Established in 1958, the company has cultivated an extensive distribution network that covers the length and breadth of Turkey. With a meticulously coordinated logistics framework, Selçuk Ecza ensures that a vast array of pharmaceutical products—from essential medicines to specialized healthcare solutions—reach pharmacies, hospitals, and healthcare institutions efficiently. This seamless operation is buoyed by the company’s ability to adapt to the ever-changing regulatory environment and consumer demands, thereby ensuring its relevance in the market for decades. The essence of Selçuk Ecza’s business model lies in its comprehensive approach to distribution, where it capitalizes on economies of scale to ensure cost-effectiveness while maintaining high-quality service standards. Revenue is generated primarily through the sales margins on the wide range of pharmaceuticals it distributes. The company’s proficiency in maintaining robust relationships with global pharmaceutical giants and local suppliers alike underpins its substantial market share. Furthermore, by embracing technological advancements, such as real-time inventory management systems, Selçuk Ecza optimizes its supply chain operations, minimizing delays and maximizing efficiency. This strategic prowess not only cements its position as a leading distributor in Turkey but also fosters sustainable growth by continuously aligning with the dynamic healthcare industry.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Selcuk Ecza Deposu Ticaret ve Sanayi AS's most recent financial statements, the company has Operating Margin of 3%.